Advances in Therapy for Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer Patients Who Have Experienced Progression After Treatment with CDK4/6 Inhibitors

Approximately 70% of breast cancer (BC) cases are hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) BC. Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors have acted as star drugs for reversing endocrine therapy (ET) resistance and improving the prognosis...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Chao, Li, Xujun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8104980/
https://www.ncbi.nlm.nih.gov/pubmed/33976551
http://dx.doi.org/10.2147/OTT.S298720

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8104980/
https://www.ncbi.nlm.nih.gov/pubmed/33976551
http://dx.doi.org/10.2147/OTT.S298720

Ejemplares similares